Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD
Holding GLMD?
Track your performance easily

Galmed Pharmaceuticals (GLMD) Income Statement

1,259 Followers

Galmed Pharmaceuticals Income Statement

Last quarter (Q4 2023), Galmed Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Galmed Pharmaceuticals's net income was $―. See Galmed Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-$ -919.00K----
Cost of Revenue
--$ -144.48K$ -144.48K--
Gross Profit
-$ -919.00K$ 144.48K$ 144.48K--
Operating Expense
$ 9.11M$ 6.58M$ 17.65M$ 32.88M$ 30.21M$ 22.38M
Operating Income
$ -9.11M$ -7.50M$ -17.65M$ -32.88M$ -30.21M$ -22.38M
Net Non Operating Interest Income Expense
$ 26.00K$ 640.00K$ -275.00K-$ 1.19M$ 1.95M
Other Income Expense
-$ 49.00K$ -490.00K$ -414.00K$ -1.44M$ -1.92M
Pretax Income
$ -9.08M$ -6.91M$ -17.87M$ -32.47M$ -28.77M$ -20.46M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -9.08M$ -6.91M$ -17.87M$ -32.47M$ -28.77M$ -20.46M
Basic EPS
$ -0.36$ 2.50$ 0.71$ 237.60--
Diluted EPS
$ -0.36$ 2.50$ 0.71$ 237.60--
Basic Average Shares
$ 50.28M$ 2.77M$ 25.16M$ 136.65K$ 118.23K$ 117.30K
Diluted Average Shares
$ 50.28M$ 2.77M$ 25.14M$ 136.65K$ 118.23K$ 117.30K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 9.11M$ 6.58M$ 17.65M$ 32.74M$ 30.21M$ 22.38M
Net Income From Continuing And Discontinued Operation
$ -9.08M$ -6.91M$ -17.87M$ -32.47M$ -28.77M$ -20.46M
Normalized Income
$ -9.08M$ -5.08M----
Interest Expense
------
EBIT
$ -9.11M$ -6.91M$ -17.65M$ -32.88M$ -30.21M$ -20.46M
EBITDA
$ -9.09M$ -6.88M$ -17.62M$ -32.84M$ -30.17M$ -20.53M
Currency in USD

Galmed Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis